Examining the Mechanisms That Link β-amyloid and α-synuclein Pathologies

Overview

Journal Alzheimers Res Ther

Date 2012 May 2

PMID 22546279

Citations 52

Authors

Samuel E Marsh

Mathew Blurton-Jones

Affiliations

Soon will be listed here.

Abstract

β-amyloid (Aβ) and α-synuclein (α-syn) are aggregation-prone proteins typically associated with two distinct neurodegenerative disorders: Alzheimer's disease (AD) and Parkinson's disease. Yet α-syn was first found in association with AD plaques several years before being linked to Parkinson's disease or Lewy body formation. Nowadays, a large subset of AD patients (~50%) is well recognized to co-exhibit significant α-syn Lewy body pathology. Unfortunately, these AD Lewy body variant patients suffer from additional symptoms and an accelerated disease course. Basic research has begun to show that Aβ and α-syn may act synergistically to promote the aggregation and accumulation of each other. While the exact mechanisms by which these proteins interact remain unclear, growing evidence suggests that Aβ may drive α-syn pathology by impairing protein clearance, activating inflammation, enhancing phosphorylation, or directly promoting aggregation. This review examines the interactions between Aβ and α-syn and proposes potential mechanistic links between Aβ accumulation and α-syn pathogenesis.

Citing Articles

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease.

Pokrzyk J, Kulczynska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B Int J Mol Sci. 2025; 26(5).

PMID: 40076562 PMC: 11900921. DOI: 10.3390/ijms26051935.

Design and Development of Natural-Product-Derived Nanoassemblies and Their Interactions with Alpha Synuclein.

Banerjee I, Das A, Biggs M, Phan C, Cutter L, Ren A Biomimetics (Basel). 2025; 10(2).

PMID: 39997105 PMC: 11852371. DOI: 10.3390/biomimetics10020082.

Role of Oxidative Stress in Blood-Brain Barrier Disruption and Neurodegenerative Diseases.

Kim S, Jung U, Kim S Antioxidants (Basel). 2025; 13(12.

PMID: 39765790 PMC: 11673141. DOI: 10.3390/antiox13121462.

Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study.

Tosun D, Hausle Z, Thropp P, Concha-Marambio L, Lamoureux J, Lebovitz R Alzheimers Dement. 2024; 20(12):8444-8460.

PMID: 39428831 PMC: 11667524. DOI: 10.1002/alz.14276.

Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis.

Boyajian J, Islam P, Abosalha A, Schaly S, Thareja R, Kassab A Microbiome Res Rep. 2024; 3(3):29.

PMID: 39421246 PMC: 11480732. DOI: 10.20517/mrr.2024.05.

References

Tarawneh R, Galvin J . Distinguishing Lewy body dementias from Alzheimer's disease. Expert Rev Neurother. 2007; 7(11):1499-516. DOI: 10.1586/14737175.7.11.1499. View

Duka T, Duka V, Joyce J, Sidhu A . Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 2009; 23(9):2820-30. PMC: 2796901. DOI: 10.1096/fj.08-120410. View

Petersen C, Alikhani N, Behbahani H, Wiehager B, Pavlov P, Alafuzoff I . The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A. 2008; 105(35):13145-50. PMC: 2527349. DOI: 10.1073/pnas.0806192105. View

Muntane G, Dalfo E, Martinez A, Ferrer I . Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience. 2008; 152(4):913-23. DOI: 10.1016/j.neuroscience.2008.01.030. View

Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T . Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett. 2010; 486(1):19-23. DOI: 10.1016/j.neulet.2010.09.036. View

McKeith I, Dickson D, Lowe J, Emre M, OBrien J, Feldman H . Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. DOI: 10.1212/01.wnl.0000187889.17253.b1. View

Oddo S, Billings L, Kesslak J, Cribbs D, LaFerla F . Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004; 43(3):321-32. DOI: 10.1016/j.neuron.2004.07.003. View

Tseng B, Green K, Chan J, Blurton-Jones M, LaFerla F . Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2007; 29(11):1607-18. PMC: 2664168. DOI: 10.1016/j.neurobiolaging.2007.04.014. View

Khandelwal P, Dumanis S, Herman A, Rebeck G, Moussa C . RETRACTED: Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci. 2011; 49(1):44-53. PMC: 3246111. DOI: 10.1016/j.mcn.2011.09.002. View

10.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

11.

Rosenberg C, Pericak-Vance M, Saunders A, Gilbert J, Gaskell P, Hulette C . Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. Acta Neuropathol. 2000; 100(2):145-52. DOI: 10.1007/s004019900155. View

12.

Oddo S . The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008; 12(2):363-73. PMC: 3822529. DOI: 10.1111/j.1582-4934.2008.00276.x. View

13.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M . beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(21):12245-50. PMC: 59799. DOI: 10.1073/pnas.211412398. View

14.

David D, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini M . Proteasomal degradation of tau protein. J Neurochem. 2002; 83(1):176-85. DOI: 10.1046/j.1471-4159.2002.01137.x. View

15.

Hamilton R . Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000; 10(3):378-84. PMC: 8098522. DOI: 10.1111/j.1750-3639.2000.tb00269.x. View

16.

Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman B . Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci. 2011; 31(41):14508-20. PMC: 3587176. DOI: 10.1523/JNEUROSCI.1560-11.2011. View

17.

Lee J, Tran T, Tansey M . Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol. 2009; 4(4):419-29. PMC: 3736976. DOI: 10.1007/s11481-009-9176-0. View

18.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

19.

Postina R . A closer look at alpha-secretase. Curr Alzheimer Res. 2008; 5(2):179-86. DOI: 10.2174/156720508783954668. View

20.

Mackenzie I . Activated microglia in dementia with Lewy bodies. Neurology. 2000; 55(1):132-4. DOI: 10.1212/wnl.55.1.132. View